NCT00086203 2015-03-25
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
FDA Office of Orphan Products Development
Phase 2 Completed
FDA Office of Orphan Products Development
Point Therapeutics
Point Therapeutics
Point Therapeutics